Antigen presentation on artificial acellular substrates: Modular systems for flexible, adaptable immunotherapy

Expert Opinion on Biological Therapy

Volumn 9, Issue 4, 2009, Pages 451-464

  Steenblock, Erin R ^a   Wrzesinski, Stephen H ^b   Flavell, Richard A ^c   Fahmy, Tarek M ^a  

^a YALE UNIVERSITY   (United States)

^b YALE CANCER CENTER   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Adoptive cell transfer; Artificial antigen presenting cell; Cancer; Immunotherapy; Vaccines

Indexed keywords

CD3 ANTIBODY; CYCLOPHOSPHAMIDE; LATEX; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MONOCLONAL ANTIBODY CD28; OKT 3; POLYGLACTIN; POLYGLYCOLIC ACID; POLYMER; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 7; T LYMPHOCYTE ANTIGEN; TYROSINASE RELATED PROTEIN 2;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG COATING; DRUG RELEASE; FIBROSARCOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CARCINOMA; LUNG TUMOR; LYMPHOMA; MASTOCYTOMA; MELANOMA; METASTASIS; NONHUMAN; REVIEW; T LYMPHOCYTE; THYMOMA;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; HUMANS; IMMUNOTHERAPY, ACTIVE; VACCINES, ACELLULAR;

EID: 67649289946     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902849216     Document Type: Review

References (87)

1. Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-2715
2. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106 (Pubitemid 46160986)
3. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-1476 (Pubitemid 46871329)
4. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006;6:204-216 (Pubitemid 43292564)
5. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308
6. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-675 (Pubitemid 37328821)
7. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 2005;28:53-62 (Pubitemid 40075938)
8. Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat Med 2001;7:1159-1162 (Pubitemid 33010027)
9. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449:419-426 (Pubitemid 47509552)
10. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-480 (Pubitemid 38667904)
11. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008;29:372-383
12. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007;220:129-150 (Pubitemid 350045575)
13. Oelke M, Maus MV, Didiano D, et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003;9:619-624 (Pubitemid 36597110)
14. Kim JV, Latouche J, Rivière I, Sadelain M. The ABCs of artificial antigen presentation. Nat Biotechnol 2004;22:403-410 (Pubitemid 38451370)
15. Oelke M, Krueger C, Giuntoli RL, Schneck JP. Artificial antigen-presenting cells: artificial solutions for real diseases. Trends Mol Med 2005;11:412-420 (Pubitemid 41254044)
16. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-238 (Pubitemid 37323223)
17. Acuto O, Bartolo VD, Michel F. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev Immunol 2008;8:699-712
18. Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med 1976;295:704-710
19. Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med 1976;295:765-770
20. Engelhard VH, Strominger JL, Mescher M, Burakoff S. Induction of secondary cytotoxic T lymphocytes by purified HLA-A and HLA-B antigens reconstituted into phospholipid vesicles. Proc Natl Acad Sci USA 1978;75:5688-5691 (Pubitemid 9101459)
21. Finberg R, Mescher M, Burakoff SJ. The induction of virus-specific cytotoxic T lymphocytes with solubilized viral and membrane proteins. J Exp Med 1978;148:1620-1627 (Pubitemid 9084036)
22. Herrmann SH, Mescher MF. Lymphocyte recognition of H-2 antigen in liposomes. J Supramolecular Struct Cell Biochem 1981;16:121-131 (Pubitemid 12176753)
23. Weinberger O, Herrmann SH, Greenstein JL, et al. The ability of Ia and H-2Kk-bearing membranes to replace the antigenpresenting cell in an H-2Kk allogeneic cytotoxic T cell response. Eur J Immunol 1985;15:1013-1018 (Pubitemid 15246831)
24. Prakken B, Wauben M, Genini D, et al. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'. Nat Med 2000;6:1406-1410
25. Giannoni F, Barnett J, Bi K, et al. Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C θ translocation to the T cell plasma membrane. J Immunol 2005;174:3204-3211 • Clustering of aAPC stimuli in microdomains to induce T cell capping is described.(Pubitemid 40354022)
26. Zappasodi R, Nicola MD, Carlo-Stella C, et al. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica 2008;93:1523-1534
27. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20 (Pubitemid 32144788)
28. Casey KA, Mescher MF. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. J Immunol 2007;178:7640-7648 (Pubitemid 46898034)
29. Curtsinger J, Deeths MJ, Pease P, Mescher MF. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. J Immunol Methods 1997;209:47-57 (Pubitemid 28032143)
30. Curtsinger JM, Lins DC, Mescher MF. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. J Immunol 1998;160:3236-3243 (Pubitemid 28164712)
31. Curtsinger JM, Schmidt CS, Mondino A, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999;162:3256-3262 (Pubitemid 29313572)
32. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003;197:1141-1151 (Pubitemid 36570069)
33. Curtsinger JM, Valenzuela JO, Agarwal P, et al. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005;174:4465-4469 (Pubitemid 40504523)
34. Curtsinger JM, Lins DC, Johnson CM, Mescher MF. Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol 2005;175:4392-4399
35. Deeths MJ, Mescher MF. B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Eur J Immunol 1997;27:598-608 • Evidence is presented that proliferation is dependent on aAPC ligand density. (Pubitemid 27110570)
36. Deeths MJ, Mescher MF. ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1. Eur J Immunol 1999;29:45-53 (Pubitemid 29043521)
37. Deeths MJ, Kedl RM, Mescher MF. CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol 1999;163:102-110 • Activation-induced non-responsiveness caused by IL-2 withdrawal is discussed. (Pubitemid 29295830)
38. Mescher MF. Surface contact requirements for activation of cytotoxic T lymphocytes. J Immunol 1992;149:2402-2405 •• The critical importance of large, continuous area of contact for T cell activation is examined.
39. Jiang X, Lu X, Liu R, et al. HLA tetramer based artificial antigen-presenting cells efficiently stimulate CTLs specific for malignant glioma. Clin Cancer Res 2007;13:7329-7334
40. Lu X, Jiang X, Liu R, et al. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response. Cancer Lett 2008;271:129-139
41. Levine BL, Bernstein WB, Connors M, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159:5921-5930 (Pubitemid 127471527)
42. Levine BL, Cotte J, Small CC, et al. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998;7:437-448 (Pubitemid 28516354)
43. Levine BL, Mosca JD, Riley JL, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996;272:1939-1943 (Pubitemid 26234505)
44. Maus MV, Riley JL, Kwok WW, et al. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clin Immunol 2003;106:16-22 (Pubitemid 36263297)
45. Oelke M, Schneck JP. HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement. Clin Immunol 2004;110:243-251 (Pubitemid 38402004)
46. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-5239
47. Acquavella N, Kluger H, Rhee J, et al. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother 2008;31:569-576
48. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-696
49. Fahmy TM, Fong PM, Goyal A, Saltzman WM. Targeted for drug delivery. Mater Today 2005;8:18-26 (Pubitemid 41023877)
50. Mohamed F, van der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 2008;97:71-87
51. Pridgen EM, Langer R, Farokhzad OC. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomed 2007;2:669-680 (Pubitemid 350268246)
52. Shalaby WSW, Yeh H, Woo E, et al. Absorbable microparticulate cation exchanger for immunotherapeutic delivery. J Biomed Mater Res Part B Appl Biomater 2004;69:173-182 (Pubitemid 38619775)
53. Fahmy TM, Samstein RM, Harness CC, Mark Saltzman W. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005;26:5727-5736 (Pubitemid 40616843)
54. Steenblock ER, Fahmy TM. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther 2008;16:765-772 • Delivery of cytokines from aAPC in paracrine manner is described.
55. Rogers J, Mescher MF. Augmentation of in vivo cytotoxic T lymphocyte activity and reduction of tumor growth by large multivalent immunogen. J Immunol 1992;149:269-276
56. Mescher MF, Rogers JD. Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide J Immunotherapy Emphasis Tumor Immunol 1996;19:102-112
57. Mitchell MS, Kan-Mitchell J, Morrow PR, et al. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin Cancer Res 2004;10:76-83 (Pubitemid 38114164)
58. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915 (Pubitemid 39273730)
59. Riddell SR, Walter BA, Gilbert MJ, Greenberg PD. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 1994;14(Suppl 4):S78-84
60. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044
61. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555 (Pubitemid 26150682)
62. Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999;5:34-41
63. Brodie SJ, Patterson BK, Lewinsohn DA, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest 2000;105:1407-1417 (Pubitemid 30322406)
64. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854 (Pubitemid 35231542)
65. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168-16173 (Pubitemid 35462767)
66. Goldberg J, Shrikant P, Mescher MF. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol 2003;170:228-235
67. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005;115:1616-1626. (Pubitemid 40814670)
68. Durai M, Krueger C, Ye Z, et al. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother 2008;58:209-20 • The first study, to our knowledge, to show in vivo efficacy of aAPC expanded T cells in control of solid tumor growth.
69. Levine BL, Bernstein WB, Aronson NE, et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8:47-53 (Pubitemid 34101728)
70. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103:17372-17377 (Pubitemid 44788976)
71. Fowler DH, Odom J, Steinberg SM, et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12:1150-1160
72. Laport GG, Levine BL, Stadtmauer EA, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003;102:2004-2013 (Pubitemid 37122373)
73. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107:1325-1331 (Pubitemid 43242365)
74. Carroll RG, Riley JL, Levine BL, et al. The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. Semin Immunol 1998;10:195-202 (Pubitemid 28347036)
75. Lu X, Humeau L, Slepushkin V, et al. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med 2004;6:963-973 (Pubitemid 40228111)
76. Lu X, Yu Q, Binder GK, et al. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol 2004;78:7079-7088 (Pubitemid 38781546)
77. Powell DJ, Levine BL. Adoptive T-cell therapy for malignant disorders. Haematologica 2008;93:1452-1456
78. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81 (Pubitemid 43765799)
79. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. J Chemother 2004;16(Suppl 4):94-97 (Pubitemid 40065293)
80. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-436 (Pubitemid 36649037)
81. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42:439-462 (Pubitemid 36700404)
82. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007;101:937-949 (Pubitemid 47040874)
83. Sledge GW, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer 2003;39:1668-1675 (Pubitemid 36897602)
84. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318
85. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492 (Pubitemid 16212345)
86. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007;25:243-265 (Pubitemid 46697909)
87. Klebanoff CA, Khong HT, Antony PA, et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005;26:111-117